Compared to other SHL, Kovaltry, gives your patients more coverage over a typical week with 2x-weekly or 3x-weekly dosing
Based on a head-to-head study comparing the pharmacokinetic profiles of Kovaltry vs. rAHF-PFM
All data were derived from a popPK-based simulation of a typical steady-state profile of a switch from 30 IU/kg rAHF-PFM to 30 IU/kg Kovaltry 2x-weekly or 3x-weekly. The popPK model provided an accurate description of chromogenic assay data (n=18).1
Adapted from Shah et al. 2017
*Example patient only for illustrative purposes. PopPK, population PK; rAHF-PFM, antihemophilic factor (recombinant) plasma/albumin-free method.
All data were derived from a popPK-based simulation of a typical steady-state profile of a switch from 30 IU/kg rAHF-PFM to 30 IU/kg Kovaltry 2x-weekly or 3x-weekly. The popPK model provided an accurate description of chromogenic assay data (n=18).1
Adapted from Shah et al. 2017
*Example patient only for illustrative purposes. PopPK, population PK; rAHF-PFM, antihemophilic factor (recombinant) plasma/albumin-free method.